Poly(ethylene) Glycol Conjugates of Biopharmaceuticals in Drug Delivery

Modern Biopharmaceuticals: Design, Development and Optimization

Volumn 4, Issue , 2008, Pages 1393-1418

  Bentley, Michael D ^a   Bossard, Mary J ^a   Burton, Kevin W ^a   Viegas, Tacey X ^a  

^a NEKTAR THERAPEUTICS   (United States)

Author keywords

Globular proteins; Parenteral drugs; Polymer; Proteolytic; Yamaoka

Indexed keywords

EID: 84871848672     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527620982.ch57     Document Type: Chapter

References (65)

1. Abuchowski, A., Van Es, T., Palzuk, N.C., Davis, F. F., Alteration of immunological properties of bovine serum albumin covalent attachment of polyethylene glycol, J. Biol. Chem. 252, 3578-3581, 1977.
2. Morpurgo, M., Veronese, F. M., Conjugates of peptides and protein polyethylene glycols, Methods Mol Biol. 283, 45-70, 2004.
3. Pasut, G., Guiotto, A., Veronese, F. M., Protein, peptide, and non-peptide drug PEGylation for therapeutic application, Expert Opin. Ther. Patents 14(5), 1-36, 2004.
4. Shorr, R.G. L., Bentley, M., Zhao, S., Parker, R., Whittle, B., Poly(ethylene glycol) conjugation of protein and small molecule drugs, in Drug Delivery Systems in Cancer Therapy (D.M. Brown, Ed.), Humana Press, Totowa, NJ, 2003, pp. 137-174.
5. Bentley, M. D., Harris, J. M., Kozlowski, A., Heterobifunctional derivatives of poly(ethylene glycol) and methods for their preparation, US patent 6,448,369, 2002.
6. Harris, J. M., Introduction to biotechnical and biomedical applications of poly(ethylene glycol), in Poly(ethylene glycol) Chemistry, Biotechnical and Biomedical Applications (J.M. Harris, Ed.), Plenum Press, New York, 1992, pp. 1-14.
7. Working, P., Newman, M.S., Johnson, J., Cornacoff, J. B., Safety of Poly(ethylene glycol) and poly(ethylene glycol) derivatives, in Poly(ethylene glycol) Chemistry and Biological Applications (J.M. Harris and S. Zalipsky, Eds.), ACS Symposium Series 680, ACS, Washington, DC, 1997, pp. 45-57.
8. Antonsen, K. P., Hoffman, A. S., Water structure of PEG solutions by differential scanning calorimetry measurements, in Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical applications (J.M. Harris, Ed.), Plenum Press, New York, 1992, pp. 15-28.
9. Yamaoka, T., Tabata, Y., Ikada, Y., Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice, J. Pharmac. Sci. 83, 601-606, 1994.
10. Yamaoka T., Tabata, Y., Ikada, Y., Fate of water soluble polymers administered via different routes, J. Pharmac. Sci. 84, 349-354, 1995.
11. Smyth, H., Carpenter, C., Shaffer, C., The toxicity of high molecular weight polyethylene glycols: chronic oral and parenteral adminis-tration, Am. Pharmac. Ass. Sci Ed. 36, 157-160, 1947.
12. Carpenter, C., Woodside, M., Kinkead, E., King, J., Sullivan, L., Response of dogs to repeated intravenous injection of polyethylene glycol 4000 with notes on excretion and sensitization, Toxicol. Appl. Pharmacol. 18, 35-40, 1971.
13. Nathan, A., Zalipsky, S., Ertel, S., Agathos, S., Yarmush, M., Kohn, J., Copolymers and polyethylene glycol: a new family of functional drug carriers, Bioconjugate Chem. 4, 54-62, 1993.
14. Shaffer, C., Critchfield, F., Chemical and physical examination of some polyethylene glycols, Am. Pharmac. Ass. Sci Ed. 39, 340-344, 1950.
15. Harris, J. M., Kozlowski, A., Polyethylene glycol and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications, US patent 5672662, 1997.
16. Carter, M. C., Meyerhoff, M. E., Instability of succinyl ester linkages in O2-monosuccinyl cyclic AMP-protein conjugates at neutral pH, J. Immunol. Methods 81, 245-257, 1985.
17. Abuchowski, A., Kazo, G.M., Verhoest, Jr., C. R., Van Es, T., Kafkewitz, D., Nocci, M.L., Viau, A.T., Davis, F. F., Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates, Cancer Biochem. Biophys. 7, 175-186, 1984.
18. Herschfield, M.S., Buckley, R. H., Greenberg, M.L., Melton, A. L., Schiff, R., Hatem, C., Kurzberg, J., Markert, M.L., Kobayashi, R. H., Kobayashi, A. L., Abuchowski, A., Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase, N. Engl. J. Med. 316, 589-596, 1987.
19. Dolence, E. K., Hu, C., Tsang, R., Sanders, C. G., Osaki, S., Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces, US patent 5 650234, 1997.
20. Wang, Y., Youngster, S., Bausch, J., Zhang, R., McNemar, C., Wyss, D. F., Identification of the major positional isomer of pegylated interferon alpha-2b, Biochemistry 39, 10634-10640, 2000.
21. Kinstler, O. B., Brems, D.N., Lauren, S. L., Paige, A. G., Hamburger, J. B., Treuheit, M.J., Characterization and stability of N-terminally pegylated rhG-CSF, Pharmac. Res. 13, 996-1002, 1995.
22. Bentley, M. D., Harris, J. M., Poly(ethylene) glycol aldehyde hydrates and related polymers and applications in modifying amines, US patent 5 990237, 1999.
23. Gais, H.J., Rupert, S., Modification and immobilization of proteins with polyethylene glycol tresylates and polysaccharide tresylates: evidence suggesting a revision of the coupling mechanism and structure of the polymer-polymer linkage, Tetrahedron Lett. 36, 3837-3838, 1995.
24. Shen, X., N-maleimidyl polymer derivatives, US patent 6602498, 2003.
25. Thw PDR® Electronic Library, ©2004, published by Thomson PDR, Montvale, NJ, USA.
26. Greenwald, R. B., Choe, Y. H., McGuire, J., Conover, C. D., Effective drug delivery by PEGylated drug conjugates, Adv. Drug Deliv. Rev. 55, 217-250, 2003.
27. Wylie, D. C., Voloch, M., Lee, S., Liu, Y.-H., Cannon-Carlson, S., Cutler, C., Pramanik, R., Carboxylated histidine is a pH-dependent product of PEGylation with SC-PEG, Pharmac. Res. 18, 1354-1360, 2001.
28. Grace, M., Youngster, S., Gitlin, G., Sydor, W., Xie, L., Westreich, L., Jacobs, S., Brassard, D., Bausch, J., Bordens, R., Structural and biologic characterization of PEGylated recombinant IFN-α2b, J. Interferon Cytokine Res. 21, 1103-1115, 2001.
29. Monkarsh, S. P., Ma, Y., Aglione, A., Bailon, P., Ciolek, D., DeBarbieri, B., Graves, M.C., Hollfelder, K., Hanspeter, M., Palleroni, A., Porter, J. E., Russoman, E., Roy, S., Pan, Y.-C. E., Positional isomers of monopegylated interferon α-2a, isolation, characterization, and biological activity, Anal. Biochem. 247, 434-440, 1992.
30. Nieforth, K. A., Nadeau, R., Paterl, I., Mould, D., Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects, Clin. Pharmacol. Ther. 59, 636-646, 1996.
31. Bailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L., Fung, W.-J., Porter, J. E., Ehrlich, G. K., Pan, W., Xu, Z.-X., Modi, M.W., Farid, A., Berthold, W., Rational design of a potent, long-lasting form of interferon: a 40kda branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C, Bioconjugate Chem. 12, 195-202, 2001.
32. Bailon, P., Berthold, W., Polyethylene glycolconjugated pharmaceutical proteins, Pharmac. Sci. Technol. Today 1, 352-356, 1998.
33. Reddy, K. R., Modi, M.W., Pedder, S., Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C, Adv. Drug Deliv. Rev. 54, 571-586, 2002.
34. Pepinsky, R. B., Lepage, D. J., Gill, A., Chakraborty, A., Vaidyanathan, S., Green, M., Baker, D.P., Whalley, E., Hochman, P. S., Martin, P., Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-β-1a with a preserved in vitro bioactivity, J. Pharmac. Exp. Ther. 296, 1059-1066, 2001.
35. Karpusas, M., Nolte, M., Benton, C. B., Meier, W., Lipscomb, W. N., Goelz, S., The crystal structure of human interferon beta at 2.2-Å resolution, Proc. Natl Acad. Sci. USA 94, 11813-11818, 1997.
36. Pepinsky, B., Runkel, L., Brickelmaier, M., Whitty, A., Hochman, P., Newton, M.A., Polymer conjugates of interferon beta-1a and uses, US patent application 2003/0021765 A1, 2003.
37. Sawlivich, W., Polyol-IFN-beta conjugates, Patent publication WO9955377, 2000.
38. Kopchick, J. J., Parkinson, C., Stevens, E. C., Trainer, P. J. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly, Endocr. Rev. 23, 623-646, 2002.
39. Kinstler, O. B., Gabriel, N. E., Farrar, C. E., De-Prince, R. B., N-terminally chemically modified protein compositions and methods, US patent 5 985265, 1999, and N-terminally chemically modified protein compositions and methods, US patent 5 824784, 1998.
40. Kinstler, O. B., Brems, D.N., Lauren, S. L., Paige, A. G., Hamburger, J. B., Treuheit, M.J., Characterization and stability of N-terminally PEGylated rhG-CSF, Pharmac. Res. 13, 996-1002, 1996.
41. Boyd, M.R., Gustafson, K. R., McMahon, J. B., Shoemaker, R. H., O'Keefe, B. R., Mori, T., Gulakowski, R. J., Wu, L., Rivera, M.I., Laurencot, C. M., Currens, M.J., Cardellina II, J. H., Buckheit, R.W., Nara, P. L., Pannell, L. K., Sowder II, R. C., Henderson, L. E., Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development, Antimicrob. Ag. Chemother. 41, 1521-1530, 1997.
42. Bolmstedt, A. J., O'Keefe, B. R., Shenoy, S. R., McMahon, J. B., Boyd, M.R., Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide specific manner, Mol. Pharmacol. 59, 949-954, 2001.
43. Barrientos, L. G., O'Keefe, B. R., Bray, M., Sanchez, A., Gronenborn, A. M., Boyd, M., Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus, Antiviral Res. 58, 47-56, 2003.
44. Green, M.E., Roberts, M., Goodin, R., Boyd, M.R., Mori, T., O'Keefe, B. R., Site-specific modification of a mutant cyanovirin-N with a large poly(ethylene glycol) moiety yields a potent anti-HIV agent with reduced toxicity in mice, J. Controlled Rel. Soc. 403, 2003, poster abstract.
45. Botos, I., O'Keefe, B. R., Shenoy, S. R., Cartner, L. K., Ratner, D. M., Seeberger, P. H., Boyd, M.R., Wlodawer, A., Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides, J. Biol. Chem. 277, 34336-34342, 2002.
46. Bewley, C. A., Gustafson, K. R., Boyd, M.R., Covell, D. G., Bax, A., Clore, M., Gronenborn, A. M., Nat. Struct. Biol. 5, 571-578, 1998.
47. Green, M.E., Roberts, M., Goodin, R., Zhang, Y., Novak, M., Bossard, M.J., Case study for site-specific peg-protein modification: peg-cyanovirin-N, a potential anti-HIV agent, AAPS, poster # W5048, 2003.
48. Folkers, K., Bowers, C.Y., LJungquist, A., Tang, P-F.L., Louisa, Kobota, M., Feng, D.-M., Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine, EP patent 377665, 1995.
49. El-Tayar, N., Zhao, X., Bentley, M. D., PEGLHRH analog conjugates, US patent 6 433135B1, 2002.
50. He, H., Murby, S., Warhurst, G., Gifford, L., Walker, D., Ayrton, J., Eastmond, R., Rowland, M., Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and Dpeptides, J. Pharmac. Sci. 87, 626-633, 1998.
51. Kim, J., Park, K., Glucose binding property of pegylated concanavalin A, Pharmac. Res. 18, 794-799, 2001.
52. Roberts, M.J., Bentley, M. D., Harris, J. M., Chemistry for peptide and protein PEGylation, Adv. Drug Deliv. Rev. 54, 459-476, 2002.
53. Felix, M., Site-specific poly(ethylene glycol) PEGylation of peptide, in Poly(ethylene glycol) Chemistry and Biological Applications (J.M. Harris and S. Zalipsky, Eds.), ACS Symposium Series 680, ACS, Washington, DC, 1997, chap. 16, pp. 218-238.
54. Kwok, K., McKenzie, D. L., Evers, D. L., Rice, K. G., Formulation of highly soluble poly(ethylene glycol)-peptide DNA condensates, J. Pharmac. Sci. 87, 996-1003, 1999.
55. Bedu-Addo, F., Moreadith, R., Advant, S., Preformulation development of recombinant pegylated staphylokinase SY 161 using statistical design, AAPS Pharm., Sci. 4, article 19, 2002, www.aaps.org..
56. Callahan, W., Narhi, L., Kosky, A., Treuheit, M., Sodium chloride enhances the storage and conformational stability of BDNF and PEG-BDNF, Pharmac. Res. 18, 261-266, 2001.
57. Huber, J. D., Campos, C. R., Egleton, R. D., Witt, K., Guo, L., Roberts, M.J., Bentley, M.D., Davis, T. P., Conjugation of low molecular weight poly(ethylene glycol) to biphalin enhances antinociceptive profile, J. Pharmac. Sci. 92, 1377-1385, 2003.
58. Heller, M., Carpenter, J., Randolph, T., Conformational stability of lyophilized PEGylated proteins in a phase-separating system, J. Pharmac. Sci. 88, 58-64, 1999.
59. Delgado, C., Malmsten, M., Van Alstine, J., Analytical partitioning of poly(ethylene glycol) modified proteins, J. Chromatogr. 692, 263-272, 1997.
60. Habeeb, A. F. S. A., Determination of free amino groups in proteins by trinitrobenzenesulfonic acid, Anal. Biochem. 14, 328-336, 1966.
61. Karr, L. J., Donnelly, D. M., Kozlowski, A., Harris, J. M., Use of poly(ethylene glycol)-modified antibody in cell extraction, Methods Enzymol. 228, 377-390, 1994.
62. Riddles, P.W., Blakely, R. L., Zerner, B., Ellman's reagent: 5,5β-dithiobis(2-nitrobenzoic acid)-a reexamination, Anal Biochem. 94, 75-81, 1979.
63. Kinstler, O. B., Gabriel, N. E., Farrar, C. E., De-Prince, R. B., N-terminally chemically modified protein compositions and methods, US patents 5 985265, 1999 and 5 824784, 1998.
64. Ho, D. H., Brown, N.S., Yen, A., Holmes, R., Keating, M., Abuchowski, A., Newman, R., Krakoff, I., Clinical Pharmacology of Polyethylene glycol-L-asparaginase, Drug Met. Dispos. 14, 349-352, 1986.
65. Wang, Y.-S., Youngster, S., Grace, M., Bausch, J., Bordens, R., Wyss, D.F., Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications, Adv. Drug Deliv. Rev. 54, 547-570, 2002.